Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. CommunitiesBusiness Wire • 03/22/23
Kite's Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell LymphomaBusiness Wire • 03/21/23
Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479Business Wire • 03/20/23
The 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With a Spring Break Rally24/7 Wall Street • 03/17/23
Gilead Sciences, Inc. (GILD) Presents at Barclays 2023 Global Healthcare Conference (Transcript)Seeking Alpha • 03/15/23
Gilead Sciences, Inc. (GILD) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)Seeking Alpha • 03/07/23